2. Signaling Pathways
  3. Cytoskeleton
  4. Integrin
  5. Integrin Isoform
  6. Integrin Antagonist

Integrin Antagonist

Integrin Antagonists (53):

Cat. No. Product Name Effect Purity
  • HY-12159A
    MK-0668 mesylate
    		Antagonist
    MK-0668 mesylate is an amino acid-based, potent antagonist of unactivated VLA-4, with an IC50) of 0.13 nM in human whole blood. And MK-0668 mesylate exhibits IC50s of 0.19 nM in dogs, 0.21 nM in rhesus monkeys, and 0.4 nM in rats.
  • HY-126039
    L-739758
    		Antagonist
    L-739758 is an antagonist for αIIbβ3 integrin (platelet glycoprotein IIb/IIIa). L-739758 acts as a peptidomimetic, binds to αIIbβ3 integrin by mimicking the interaction of the RGD (arginine-glycine-aspartic acid) motif, and is involved in the blood coagulation process. L-739758 inhibits platelet aggregation, and is used for thrombosis research.
  • HY-14277AR
    Levocabastine (hydrochloride) (Standard)
    		Antagonist
    Levocabastine (hydrochloride) (Standard) is the analytical standard of Levocabastine (hydrochloride). This product is intended for research and analytical applications. Levocabastine (R 50547) hydrochloride is a potent and selective histamine H1-receptor antagonist. Levocabastine hydrochloride is also a selective, high affinity neurotensin receptor subtype 2 (NTR2) antagonist, with a Ki of 17 nM for mNTR2. Levocabastine hydrochloride can act as a VLA-4 antagonist, interferes with conjunctival eosinophil infiltration in allergic conjunctivitis (AC).
  • HY-19344R
    Lifitegrast (Standard)
    		Antagonist
    Lifitegrast (Standard) is the analytical standard of Lifitegrast. This product is intended for research and analytical applications. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease.
  • HY-124290A
    Carotegrast methyl hydrochloride
    		Antagonist
    Carotegrast methyl (AJM300) hydrochloride is an orally active and selective α4 integrin antagonist. HCA2969, an active metabolite of Carotegrast methyl hydrochloride, is a specific and dual α4β1/α4β7 integrin antagonist. Carotegrast methyl hydrochloride prevents the development of colitis in mice.
  • HY-10306
    Gantofiban
    		Antagonist
    Gantofiban is a GPIIb/IIIa integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect.
  • HY-19344S2
    Lifitegrast-d4-1
    		Antagonist
    Lifitegrast-d4-1 is deuterium labeled Lifitegrast. Lifitegrast (SAR 1118) is a potent integrin antagonist. Lifitegrast blocks the binding of intercellular adhesion molecule 1 (ICAM-1) to lymphocyte function-associated antigen 1 (LFA-1), interrupting the T cell-mediated inflammatory cycle. Lifitegrast inhibits Jurkat T cell attachment to ICAM-1 with an IC50 of 2.98 nM. Lifitegrast can be used for researching dry eye disease.
  • HY-101720
    Fradafiban
    		Antagonist
    Fradafiban is a nonpeptide platelet glycoprotein IIb/IIIa antagonist, which binds to the human platelet GP IIb/IIIa complex with a Kd value of 148 nM.
  • HY-19163
    SC-52012
    		Antagonist
    HY-19163 is an orally active fibrinogen receptor antagonist, with antiplatelet activities.
  • HY-10309R
    Sibrafiban (Standard)
    		Antagonist
    Sibrafiban (Standard) is the analytical standard of Sibrafiban. This product is intended for research and analytical applications. Sibrafiban (RO 48-3657) is the orally active, nonpeptide, double-proagent of Ro 44-3888 and a selective glycoprotein IIb/IIIa receptor antagonist. Sibrafiban inhibits platelet aggregation.
  • HY-123802
    BIO7662
    		Antagonist
    BIO7662 is a specific α4β1 antagonist. BIO7662 can be used to study α4β1 integrin-ligand interactions.
  • HY-75385A
    Zaurategrast ethyl ester sulfate
    		Antagonist
    Zaurategrast ethyl ester sulfate (CDP323 sulfate), the ethyl ester proagent of CT7758, is a α4β1/α4β7 integrin antagonist used for the treatment of inflammatory and autoimmune disorders.
  • HY-U00235
    SR121566A
    		Antagonist
    SR121566A is a novel non-peptide Glycoprotein IIb/IIIa (GP IIb-IIIa) antagonist, which can inhibit ADP-, arachidonic acid- and collagen-induced human platelet aggregation with IC50s of 46±7.5, 56±6 and 42±3 nM, respectively.